Lucira Health (LHDXQ)
OTHER OTC:LHDXQ
US Market
Holding LHDXQ?
Track your performance easily

Lucira Health (LHDXQ) Stock Forecast & Price Target

100 Followers
See the Price Targets and Ratings of:

LHDXQ Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Lucira
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LHDXQ Stock 12 Month Forecast

There Are No Analyst Ratings for LHDXQ In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

LHDXQ Financial Forecast

No data currently available

LHDXQ Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.
No data currently available

LHDXQ Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital
Hold
Reiterated
11/23/22
Yesterday, Lucira Health (Nasdaq: LHDX) announced that its COVID-19 and Flu combinaon test had received emergency use authorizaon (EUA) from FDA for point-of-care (POC) use. Per management, the test can now be used by clinicians in CLIA-waived sengs to differena te between B, which can expedite the mely inia on of relevant treatment. While this approval paves the way for US commercializaon in the healthcare seng, it is important to keep in mind that the Company originally filed for an EUA with an over-the-counter (OTC) indica on back in May. However, FDA felt that the prospecv e and retrospecv e data included in the submission did not sufficiently demonstrate minimal risk of false negav e results and therefore required that Lucira first proceed with a POC label as well as supply addional clinical data in order to proceed with an OTC label.
Bank of America Securities
$0.75
Sell
749900.00%
Upside
Reiterated
11/15/22
Lucira Health Inc. (LHDX) PT Lowered to $0.75 at BofA SecuritiesBofA Securities analyst Derik de Bruin lowered the price target on Lucira Health Inc. (NASDAQ: LHDX) to $0.75 (from $3.00) while maintaining a Underperform rating.

Best Analysts Covering Lucira Health

Which Analyst Should I Follow If I Want to Buy LHDXQ and Sell After:
1 Month
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+40.10%
reiterated a xxx
rating 2 years ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +40.10% per trade.
3 Months
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+38.00%
reiterated a xxx
rating 2 years ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +38.00% per trade.
1 Year
Derik De BruinBank of America Securities
Success Rate
3/3 ratings generated profit
100%
Average Return
+85.90%
reiterated a sell rating 2 years ago
Copying Derik De Bruin's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +85.90% per trade.
2 Years
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+97.63%
reiterated a xxx
rating 2 years ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +97.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LHDXQ Analyst Recommendation Trends

Currently, no data available
Please return soon. This page is being updated.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

LHDXQ Stock Forecast FAQ

What is LHDXQ’s average 12-month price target, according to analysts?
Currently, no data Available
What is LHDXQ’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for LHDXQ, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is LHDXQ a Buy, Sell or Hold?
      Currently, no data Available
      What is Lucira Health’s price target?
      Currently, no data Available
      What do analysts say about Lucira Health?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of LHDXQ?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis